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ORIGINAL ARTICLE
Obesity is associated with impaired immune response to
influenza vaccination in humans
PA Sheridan1,7, HA Paich1,7, J Handy2, EA Karlsson1,3, MG Hudgens4, AB Sammon1, LA Holland1, S Weir5, TL Noah6 and MA Beck1
BACKGROUND: Obesity is an independent risk factor for morbidity and mortality from pandemic influenza H1N1. Influenza is a
significant public health threat, killing an estimated 250 000 -- 500 000 people worldwide each year. More than one in ten of the
world’s adult population is obese and more than two-thirds of the US adult population is overweight or obese. No studies have
compared humoral or cellular immune responses to influenza vaccination in healthy weight, overweight and obese populations
despite clear public health importance.
OBJECTIVE: The study employed a convenience sample to determine the antibody response to the 2009 -- 2010 inactivated
trivalent influenza vaccine (TIV) in healthy weight, overweight and obese participants at 1 and 12 months post vaccination.
In addition, activation of CD8þ T cells and expression of interferon-g and granzyme B were measured in influenza-stimulated
peripheral blood mononuclear cell (PBMC) cultures.
RESULTS: Body mass index (BMI) correlated positively with higher initial fold increase in IgG antibodies detected by enzyme-
linked immunosorbent assay to TIV, confirmed by HAI antibody in a subset study. However, 12 months post vaccination, higher
BMI was associated with a greater decline in influenza antibody titers. PBMCs challenged ex vivo with vaccine strain virus,
demonstrated that obese individuals had decreased CD8þ T-cell activation and decreased expression of functional proteins
compared with healthy weight individuals.
CONCLUSION: These results suggest obesity may impair the ability to mount a protective immune response to influenza virus.
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INTRODUCTION
Influenza causes some three to five million cases of severe illness
and 250 000 -- 500 000 deaths every year around the world, even in
the absence of a major pandemic.1 Obesity is a growing health
concern of epidemic proportions in many countries;2 more than
one in ten of the world’s adult population is obese2 and more than
two-thirds of the US adult population is overweight or obese.3
In addition to co-morbidities such as cardiovascular disease and
diabetes, obesity itself is an immunosuppressive condition.4 - 6
During the recent pandemic of influenza A/H1N1/2009 (pH1N1),
obesity was recognized for the first time as an independent risk
factor for increased influenza morbidity and mortality.7 - 11
Annual vaccination is the primary strategy available for
decreasing the impact of influenza infection. No studies have
examined how obesity may affect the response to influenza
vaccination in humans. Obesity is associated with decreased
antibody response to hepatitis B vaccine12,13 and to tetanus
toxoid.14 Our work with diet-induced obese mice found greater
mortality following influenza infection and impaired innate
immune responses,15 as well as, an impaired CD8þ T-cell memory
response that increased morbidity and mortality from a secondary
influenza challenge.16 However, the effects of obesity on immune
responses to influenza vaccine have not been characterized in
humans. We therefore initiated a prospective observational study
of the effect of body mass index (BMI) on humoral and cell
mediated immune responses to influenza vaccination in humans.
Here, we report data from the first 2 years of this study.
METHODS
Study design and subjects
This is an ongoing, prospective observational study carried out at the
University of North Carolina Family Medicine Center, an academic
outpatient primary care facility in Chapel Hill, NC. Eligible participants
were adult (X18 years) patients at the Center scheduled to receive the
2009 -- 2010 seasonal trivalent influenza vaccine (TIV). Enrollment and data
analysis were conducted independently for each year because of the
annual change in vaccine composition. Exclusion criteria were immuno-
suppression, self-reported use of immunomodulator or immunosuppres-
sive drugs, acute febrile illness, history of hypersensitivity to any influenza
vaccine components, history of Guillian - Barre syndrome, or use of
theophylline preparations or warfarin.17,18 All procedures were approved
by the Biomedical Institutional Review Board at the University of North
Carolina.
In year 1 of the study (September - November 2009), we enrolled 499
participants. At enrollment, informed consent, height, weight and a
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baseline serum sample were obtained. One dose of 2009 - 2010 seasonal
TIV (0.5 ml Fluzone (Sanofi Pasteur, Swiftwater, PA, USA) containing A/
Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2) and B/Brisbane/60/
2008) was administered in the deltoid muscle. Participants (461, 92%
completion rate) returned 28 - 35 days later for a post-vaccination blood
draw. Pre- and post-vaccination serum samples were stored at 80 1C until
analyzed, whereas peripheral blood mononuclear cells (PBMCs) were
separated from a second heparinized blood sample on a Histopaque
(Sigma, St Louis, MO, USA) gradient and frozen in liquid nitrogen until
analyzed.
At the start of year 2 of the study, 74 participants who had participated
in year 1 independently re-enrolled to participate in year 2, providing us
the additional opportunity to assess immune parameters 12 months after
receipt of the 2009 - 2010 TIV.
ELISA and haemagglutination inhibition assays
IgG antibodies were quantified by enzyme-linked immunosorbent assay
using the 2009 - 2010 seasonal TIV as antigen. Vaccine was diluted and
adsorbed to microtitration plates in a carbonate coating buffer. After
washing, triplicate serum dilutions in PBS were allowed to react with
antigen, and bound antibodies were detected by a peroxidase-conjugated
goat anti-human IgG (Abcam, Cambridge, MA, USA), followed by a
chromogenic substrate. Color intensity was measured by absorbance at
450 nm. Internal control sera were included in each run. Pre- and
post-vaccination sera from each participant were tested in the same run.
The intra-assay coefficient of variation using this assay is 4%.
In order to determine serotype-specific antibody responses to the three
components of the seasonal TIV, a subset of pre- and 1 month post-vaccine
serum samples from 38 healthy weight and 38 obese participants,
matched for race, age and sex, was tested by Focus Diagnostics (Cypress,
CA, USA) for HAI antibodies against the 2009 - 2010 seasonal TIV strains.
Activation and expression of IFNc and granzyme B by
influenza-stimulated PBMCs
PBMC samples obtained from 61 participants 12 months post vaccination
(23 healthy weight (BMI 22.2 þ / 1.7), 17 overweight (BMI 27.6 þ / 1.5)
and 21 obese (BMI 35.7 þ / 4.5)) were thawed and cultured in AIM-V
serum-free media supplemented with 1% penicillin/streptomycin and 1%
glutamine. We have previously determined that our freezing method did
not alter lymphocyte cell subset numbers in samples from healthy weight
or obese individuals (data not shown). Cells were plated at 1 106 cells per
well for 120 h with or without stimulation with 6.4 hemagglutination units
of influenza A/Brisbane/59/2007 (H1N1). For the last 6 h, GolgiPlug, a
protein transport inhibitor containing Brefeldin A, (BD Biosciences, San
Jose, CA, USA) was added to all PBMC samples. PBMCs were stained with
fluorochrome-conjugated antibodies and analyzed for CD3, CD8, CD69,
interferon-g (IFNg) and granzyme B expression, using a Cyan ADP flow
cytometer (Beckman Coulter, Fullerton, CA, USA). Appropriate isotype
controls were used for each stain and data were analyzed using FlowJo
software (TreeStar, Ashland, OR, USA). CD69 is an early-activation marker
expressed on the surface of activated lymphocytes. CD8þ cytotoxic T cells
function to destroy infected cells and mediate this targeted killing through
a variety of mechanisms, including production of the functional proteins
IFNg and granzyme B.
Statistics
Associations between baseline variables and antibody response (at 1
month and 12 months post vaccination) were assessed using Spearman’s
rank correlation coefficient for continuous variables (age and BMI) and the
Kruskal - Wallis test for categorical variables (diabetes, race, sex and
smoking status). Baseline variables that were marginally associated with
ELISA antibody fold increase at 1 month post vaccination were included in
a multivariate linear regression model, with log10 antibody fold increase as
the response variable. For the matched pairs HAI substudy, response
frequencies (defined as X4-fold increase or seroconversion) between
healthy weight and obese participants were compared using McNemar’s
test. Comparisons of HAI titer fold increase between healthy weight
and obese participants were assessed by applying the Wilcoxon signed
rank test to the log of the fold increase ratio between healthy weight and
obese participants within a pair. Fold increase between paired unstimu-
lated and stimulated PBMC expression of CD69, granzyme B and IFNg was
assessed using the Wilcoxon signed rank test.
RESULTS
Characteristics of the study population
The demographics of the study population are presented in
Table 1. Our participants were 29.7% healthy weight, 33.4%
overweight and 35.5% obese. The subset of 74 participants who
were studied 12 months after receipt of the 2009 -- 2010 vaccine
were demographically similar to the overall study population
(Table 1).
ELISA and HAI titers 1 month post vaccination
As others have reported,19 age was negatively correlated with
antibody response as measured by ELISA (Po0.001). BMI was
positively correlated with antibody fold increase (Po0.001).
Antibody response was higher in females (P¼ 0.001), consistent
with previous studies of gender effect on vaccine response.20
There was a marginally significant association between race and
antibody response (P¼ 0.01), suggesting that African Americans
had slightly higher responses than whites. There was no
association of antibody response with smoking status or diabetes.
In a multivariate model of log10 antibody fold increase including
BMI, age, race and sex, both BMI and age remained significant
predictors of fold increase (P¼ 0.002 and Po0.001, respectively),
whereas race was marginally significant (P¼ 0.03) and sex was
borderline significant (P¼ 0.08). Based on the fitted model, a 10
unit increase in BMI was associated with 13% greater-fold increase
in antibody titer, whereas a 10 year increase in age was associated
with an 8% lower-fold increase in antibody titer. Age and BMI did
not interact in the model.
Pre- and post-vaccination antibody titers for the three vaccine
strains were not significantly different between the healthy weight
and obese participants. As shown in Figure 1, when examining
fold increase between pre- and post-vaccination antibody titers,
there was no difference for the A/Brisbane/59/2007 (H1N1) and A/
Brisbane/10/2007 (H3N2) strains (P¼ 0.014 and P¼ 0.09, respec-
tively), however, there was a higher-fold increase in obese
compared with healthy weight participants for B/Brisbane/60/
2008 (P¼ 0.04). Spearman’s rank correlations between the ELISA
and HAI fold increases demonstrated that the ELISA was positively
correlated with HAI results for all three of the vaccine strains: a
correlation of 0.57 (Po0.001) for A/Brisbane/59, 0.50 (Po0.001) for
A/Brisbane/10 and 0.52 (Po0.001) for B/Brisbane/60.
ELISA and HAI titers 12 months following vaccination
As shown in Figure 2a, increasing BMI was associated with a larger
drop in antibody titer to 2009 -- 2010 seasonal TIV as measured by
ELISA 12 months after vaccination. To confirm this finding
using HAI, we tested 17 matched pairs of healthy weight (BMI
22.6 þ / 1.9) and obese participants (BMI 35.4 þ /5.4) 1 and 12
months post vaccination for HAI antibodies against each
vaccine strain of virus. Although the majority of both healthy
weight and obese vaccinated participants had a decrease in
antibody titer during this interval, a larger percentage of obese
participants had a four-fold or greater drop in HAI titer at 12
months compared with healthy weight participants (Figure 2b).
Thus, these results indicate that obese individuals have a steeper
decline in vaccine antibody over time compared with healthy
weight individuals.
Obesity and immune response to influenza vaccination
PA Sheridan et al
1073
International Journal of Obesity (2012) 1072 - 1077& 2012 Macmillan Publishers Limited
Decreased activation of influenza-specific CD8þ T cells in
PBMCs obtained from obese individuals
In order to test the cellular response to influenza vaccination,
PBMCs at 12 months post vaccination were challenged ex vivo
with live vaccine strain influenza A/Brisbane/59/2007 H1N1.
PBMCs from obese participants exhibited a significantly lower
percent increase in CD8þ T cells expressing the early activation
marker CD69, than PBMCs from healthy weight participants
(P¼ 0.015) (Figure 3a), although the total numbers of CD8þ T cells
were similar (data not shown).
Table 1. Demographic characteristics of 2009--2010 and 2010 - 2011 returning study participants
Underweighta Healthy weight Overweight Obese Total
Year 1b
Enrolledc 6 (1.3) 137 (29.7) 154 (33.4) 164 (35.5) 461
Aged 45.6 +/24.0 59.7 +/17.8 52.5 +/15.6 51.6 +/12.8
Gender
Male 0 (0) 41 (8.9) 73 (15.8) 46 (9.9) 160 (34.7)
Female 6 (1.3) 96 (20.8) 81 (17.5) 118 (17.5) 301 (65.2)
Race
White 5 (1.1) 105 (22.8) 104 (22.6) 95 (20.6) 309 (67.0)
AA 0 (0) 19 (4.1) 43 (9.3) 63 (13.7) 125 (27.1)
Other 1 (0.2) 13 (2.8) 7 (1.5) 6 (1.3) 27 (5.9)
Diabetes
Yes 0 (0) 8 (1.7) 29 (6.3) 54 (11.7) 91 (19.6)
No 6 (1.3) 129 (28.0) 125 (27.1) 110 (23.9) 370 (80.4)
Year 2e
Enrolledc 0 24 (32.4) 23 (31.0) 27 (36.5) 74
Aged --- 47.6 +/17.5 54.6 +/14.1 54.8 +/11.9
Gender
Male --- 6 (8.1) 10 (13.5) 10 (13.5) 26 (35.1)
Female --- 18 (24.3) 13 (17.6) 17 (23.0) 48 (64.9)
Race
White --- 17 (22.9) 17 (22.9) 15 (20.2) 49 (66.2)
AA --- 6 (8.1) 5 (6.8) 11 (14.9) 22 (29.7)
Other --- 1 (1.4) 1 (1.4) 1 (1.4) 3 (4.1)
aBMI: underweight (o18.5), healthy weight (18.5-24.9), overweight (25-29.9), obese (430). bParticipants who completed the 2009-2010 study 22. cNumber




































































Figure 1. Obese participants do not have an impaired initial response to influenza vaccination. Boxplots of the fold increase of the
geometric mean titers of HAI response for each vaccine strain. Wilcoxon signed rank test of fold increase of healthy weight vs obese:
(a) A/Brisbane/59/2007, P¼ 0.14; (b) A/Brisbane 10/2007, P¼ 0.09; (c) B/Brisbane/60/2008, P¼ 0.04. Healthy weight n¼ 40,
obese n¼ 40.
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Decreased expression of functional proteins in influenza-specific
activated CD8þ T cells in PBMCs obtained from obese individuals
In addition to upregulating activation markers upon stimulation,
CD8þ T cells generate IFNg and express granzyme B in order to
limit influenza replication and rapidly clear the virus. PBMCs from
obese participants exhibited a significantly lower-percent increase
in activated CD8þ T cells expressing granzyme B than PBMCs
from healthy weight participants (P¼ 0.026) (Figure 3b). PBMCs
from obese and overweight participants exhibited a lower-percent
increase in activated CD8þ T cells expressing IFNg, than PBMCs
from healthy weight participants (P¼ 0.006 and P¼ 0.047,
respectively) (Figure 3c). These data indicate that obesity and
overweight in the case of IFNg, results in a decreased production
of the proteins IFNg and granzyme B.
DISCUSSION
During the 2009 H1N1 influenza pandemic, obesity was recog-
nized as an independent risk factor for increased influenza
morbidity and mortality.7 - 9 Influenza vaccination is the single
most effective method for reducing morbidity and mortality from
influenza. Despite recognition that obesity is immunosuppres-
sive,4 this is the first study to examine antibody and CD8þ T-cell
Figure 2. Obesity results in a greater decline of influenza antibodies. (a) Correlation between BMI and percent antibody drop of ELISA titers.
As the BMI increases, the drop in antibody at 12 months postvaccination is increased. Spearman’s rank correlation: r¼ 0.29 (P¼ 0.01), n¼ 74.
(b) More obese individuals have a 44-fold drop in HAI titer at 12 months post vaccination compared with healthy weight individuals
(McNemar’s test P¼ 0.16 for A/Brisbane/59, P¼ 0.32 for A/Brisbane/10 and P¼ 0.03 for B/Brisbane/60). Healthy weight n¼ 17, obese n¼ 17.
Figure 3. Obesity results in defective CD8þ T-cell activation and production of the functional proteins Granzyme B and IFNg by influenza-
stimulated PBMCs. (a) PBMCs from obese participants have a lower-percent increase in activated CD69-expressing CD8þ T cells (P¼ 0.015)
and (b) a lower-pecentage increase in activated T cells that express Granzyme B (P¼ 0.026) compared with healthy weight. (c) PBMCs from
overweight and obese participants have a lower-percent increase in activated CD8þ T cells that express IFNg (P¼ 0.047 and P¼ 0.006,
respectively). The percent increase in cell number for each population of cells was calculated between PBMCs incubated with plain media and
PBMCs incubated with influenza A virus. As such, each individual sample was compared with its own control. Bar graphs show mean percent
increase and standard error for the three groups. Healthy weight n¼ 23, overweight n¼ 17, obese n¼ 21. *indicates P-value is o0.05
compared with the healthy weight group. GrB¼Granzyme B.
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responses to influenza vaccination in healthy weight, overweight
and obese individuals.
Because obesity reduces antibody responses to hepatitis B
vaccine in adults and to tetanus vaccine in children,4,12 - 14
elevated antibody response to influenza vaccination in our obese
study participants was unexpected. Our data show that obese
individuals mount a vigorous initial antibody response to TIV.
However, a vaccine is protective only if the antibody titer is
maintained throughout the period when influenza virus is
circulating in the population. To examine the level of antibody
maintenance after vaccination, we measured antibody levels
12 months after vaccination. Increases in BMI were positively
correlated to decreases in antibody titer. More than 50% of the
obese participants had a X4-fold decrease in HAI titers to
A/Brisbane/10 and B/Brisbane/60, and 47% had a X4-fold
decrease in HAI titer to A/Brisbane/59 at 12 months compared
with 1 month post vaccination. By comparison, o25% of healthy
weight participants had a 44-fold decrease in HAI titer to
A/Brisbane/59 and B/Brisbane/60. The objectives of our ongoing
study include more precise definition of the kinetics of this
differential decline in antibody titer as well as follow-up of
participants to determine whether BMI influences the actual rates
of laboratory-confirmed influenza in vaccinated individuals. In
addition to stimulating production of influenza antigen-specific
antibodies, influenza vaccination also functions to generate a
CD8þ T-cell response. The importance of a robust CD8þ T-cell
memory response has been appreciated, and there is great
interest in developing influenza vaccines that can promote a
heightened T-cell memory response. Our own work in a murine
diet-induced obesity model demonstrated an impaired CD8þ
T-cell memory response leading to increased morbidity and
mortality from an influenza challenge.16 In addition, it has also
been suggested that there is an obesity-associated decrease in
naive T cells and T-cell diversity,21 which could contribute to the
impaired CD8þ T-cell response seen in our study.
Influenza-specific CD8þ T cells do not protect against infection,
but instead act to limit progression of disease, allow for more
rapid viral clearance and lessen the severity of disease.22 Whereas
the targets for antibodies are the proteins on the surface of the
influenza virus, the targets for CD8þ T cells are located on the
internal, highly conserved proteins of the virus, which allow for
extensive cross reactivity against multiple strains of influenza virus.
The influenza virus surface proteins have a tendency to change
frequently; as such, an antibody-based vaccine may be protective
for 1 year, but not the next.23 Because memory CD8þ T cells are
specific to internal influenza proteins that vary little from year to
year, it is likely more effective and efficient to develop influenza
vaccines which expand memory CD8þ T-cell populations, in
addition to invoking a robust antibody response.24 Indeed, CD8þ
T-cell cytotoxic activity correlates better with influenza protection
than antibody titer in an elderly population.25
We found that percentage of influenza-activated CD8þ T cells
were decreased in the obese participants, and two markers of
functional CD8þ activity, IFNg and granzyme B, were also
significantly decreased in the obese participants. CD8þ T cells
kill virus-infected cells by release of perforin and granzyme B26
and inhibit viral replication by the release of IFNg.27 The fact that
influenza-stimulated CD8þ T cells from obese individuals were
deficient in the expression of both of these proteins strongly
suggests that protection from an influenza infection may be not
be optimal in the obese population.
We report here, for the first time, that influenza vaccine
antibody levels decline significantly and CD8þ T-cell responses
are defective in obese compared with healthy weight individuals.
These findings suggest a mechanism for the increased risk of
severe disease from pH1N1 infection in the obese population. If
antibody titers and influenza vaccination-induced memory CD8þ
T-cell populations are not maintained over time by the obese
individuals, they may be at risk for suboptimal vaccine response.
Additional studies are needed to determine the risk of influenza
infection in a vaccinated obese population.
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